The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Treatment of recurrent ovarian cancer
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., & Jemal, A. (2015) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21254 · Cited by 11,853
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
Mirza, M. R., Monk, B. J., Herrstedt, J., Oza, A. M., Mahner, S., Redondo, A., Fabbro, M., Ledermann, J. A., Lorusso, D., Vergote, I., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1611310 · Cited by 2,451
Self-citationIncorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
Burger, R. A., Brady, M. F., Bookman, M. A., Fleming, G. F., Monk, B. J., Huang, H., Mannel, R. S., Homesley, H. D., Fowler, J., Greer, B. E., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104390 · Cited by 2,404
A Phase 3 Trial of Bevacizumab in Ovarian Cancer
Perren, T. J., Swart, A. M., Pfisterer, J., Ledermann, J. A., Pujade-Lauraine, E., Kristensen, G., Carey, M. S., Beale, P., Cervantes, A., Kurzeder, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103799 · Cited by 2,172
du Bois, A., Reuss, A., Pujade‐Lauraine, E., Harter, P., Ray‐Coquard, I., & Pfisterer, J. (2009) · Cancer · doi:10.1002/cncr.24149 · Cited by 1,638
Self-citationLedermann, J., Harter, P., Gourley, C., Friedlander, M., Vergote, I., Rustin, G., Scott, C. L., Meier, W., Shapira-Frommer, R., Safra, T., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70228-1 · Cited by 1,442
Self-citationSwisher, E. M., Lin, K. K., Oza, A. M., Scott, C. L., Giordano, H., Sun, J., Konecny, G. E., Coleman, R. L., Tinker, A. V., O'Malley, D. M., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30559-9 · Cited by 1,196
Pfisterer, J., Plante, M., Vergote, I., du Bois, A., Hirte, H., Lacave, A. J., Wagner, U., Stähle, A., Stuart, G., Kimmig, R., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.0913 · Cited by 754
Self-citationColeman, R. L., Brady, M. F., Herzog, T. J., Sabbatini, P., Armstrong, D. K., Walker, J. L., Kim, B.-G., Fujiwara, K., Tewari, K. S., O'Malley, D. M., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30279-6 · Cited by 609
Harter, P., Bois, A. D., Hahmann, M., Hasenburg, A., Burges, A., Loibl, S., Gropp, M., Huober, J., Fink, D., Schröder, W., et al. (2006) · Annals of Surgical Oncology · doi:10.1245/s10434-006-9058-0 · Cited by 425
Self-citationFarley, J., Brady, W. E., Vathipadiekal, V., Lankes, H. A., Coleman, R., Morgan, M. A., Mannel, R., Yamada, S. D., Mutch, D., Rodgers, W. H., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70572-7 · Cited by 413
Cytoreductive surgery for recurrent ovarian cancer: A meta-analysis
Bristow, R. E., Puri, I., & Chi, D. S. (2009) · Gynecologic Oncology · doi:10.1016/j.ygyno.2008.08.033 · Cited by 374
Chi, D. S., McCaughty, K., Diaz, J. P., Huh, J., Schwabenbauer, S., Hummer, A. J., Venkatraman, E. S., Aghajanian, C., Sonoda, Y., Abu‐Rustum, N. R., et al. (2006) · Cancer · doi:10.1002/cncr.21845 · Cited by 350
Aghajanian, C., Goff, B., Nycum, L. R., Wang, Y. V., Husain, A., & Blank, S. V. (2015) · Gynecologic Oncology · doi:10.1016/j.ygyno.2015.08.004 · Cited by 320
Prospective Validation Study of a Predictive Score for Operability of Recurrent Ovarian Cancer
Harter, P., Sehouli, J., Reuß, A., Hasenburg, A., Scambia, G., Cibula, D., Mahner, S., Vergote, I. B., Reinthaller, A., Burges, A., et al. (2011) · International Journal of Gynecological Cancer · doi:10.1097/igc.0b013e31820aaafd · Cited by 297
Self-citationHormonal Maintenance Therapy for Women With Low-Grade Serous Cancer of the Ovary or Peritoneum
Gershenson, D. M., Bodurka, D. C., Coleman, R. L., Lu, K. H., Malpica, A., & Sun, C. C. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.0632 · Cited by 279
Poveda, A. M., Selle, F., Hilpert, F., Reuss, A., Savarese, A., Vergote, I., Witteveen, P., Bamias, A., Scotto, N., Mitchell, L., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.1408 · Cited by 232
Clinical Trials in Recurrent Ovarian Cancer
Friedlander, M., Trimble, E., Tinker, A., Alberts, D., Avall-Lundqvist, E., Brady, M., Harter, P., Pignata, S., Pujade-Lauraine, E., Sehouli, J., et al. (2011) · International Journal of Gynecological Cancer · doi:10.1097/igc.0b013e31821bb8aa · Cited by 224
Self-citationHarter, P., Muallem, Z. M., Buhrmann, C., Lorenz, D., Kaub, C., Hils, R., Kommoss, S., Heitz, F., Traut, A., & du Bois, A. (2011) · Gynecologic Oncology · doi:10.1016/j.ygyno.2011.02.014 · Cited by 200
Self-citationDu Bois, A., Vergote, I., Ferron, G., Reuss, A., Meier, W., Greggi, S., Jensen, P. T., Selle, F., Guyon, F., Pomel, C., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.5501 · Cited by 176
Self-citationPoveda, A., Vergote, I., Tjulandin, S., Kong, B., Roy, M., Chan, S., Filipczyk-Cisarz, E., Hagberg, H., Kaye, S. B., Colombo, N., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdq352 · Cited by 163
Secondary Cytoreductive Surgery for Patients with Recurrent Epithelial Ovarian Carcinoma
Scarabelli, C., Gallo, A., & Carbone, A. (2001) · Gynecologic Oncology · doi:10.1006/gyno.2001.6404 · Cited by 140
Zang, R., Harter, P., S., D., Sehouli, J., Jiang, R., Trope, C. G., Ayhan, A., Cormio, G., Xing, Y., Wollschlaeger, K., et al. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.328 · Cited by 135
Self-citationRucaparib: First Global Approval
Syed, Y. Y. (2017) · Drugs · doi:10.1007/s40265-017-0716-2 · Cited by 115
Fifth Ovarian Cancer Consensus Conference: individualized therapy and patient factors
McGee, J., Bookman, M. A., Harter, P., Marth, C., McNeish, I. A., Moore, K. N., Poveda, A. M., Hilpert, F., Hasegawa, K., Bacon, M. A., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx010 · Cited by 65
Self-citationLorusso, D., Scambia, G., Pignata, S., Sorio, R., Amadio, G., Lepori, S., Mosconi, A. M., Pisano, C., Mangili, G., Maltese, G., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv608 · Cited by 55
Self-citationPujade-Lauraine, É., Ledermann, J. A., Penson, R. T., Oza, A. M., Korach, J., Huzarski, T., Poveda, A. M., Pignata, S., Friedlander, M. L., & Colombo, N. (2017) · Gynecologic Oncology · doi:10.1016/j.ygyno.2017.03.505 · Cited by 50
Self-citationAbudou, M., Zhong, D., Wu, T., & Wu, X. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005589.pub2 · Cited by 48
Tian, W., Jiang, R., Cheng, X., et al. (2010) · Journal of Surgical Oncology · doi:10.1002/jso.21491 · Cited by 48
Leary, A. F., Quinn, M. A., Fujiwara, K., Coleman, R. L., Kohn, E. C., Sugiyama, T., Glasspool, R. M., Ray-Coquard, I., Colombo, N., Bacon, M. A., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw662 · Cited by 40
van de Laar, R., Massuger, L. F. A. G., Gorp, T. V., IntHout, J., Zusterzeel, P. L. M., & Kruitwagen, R. F. P. M. (2015) · Gynecologic Oncology · doi:10.1016/j.ygyno.2015.02.004 · Cited by 34
Prognostic Factors for Complete Debulking in First- and Second-Line Ovarian Cancer
Harter, P., Hilpert, F., Mahner, S., Kommoss, S., Heitz, F., Pfisterer, J., & du Bois, A. (2009) · International Journal of Gynecological Cancer · doi:10.1111/igc.0b013e3181bffb3f · Cited by 32
Self-citationMantia-Smaldone, G. M., Ronner, L., Blair, A., Gamerman, V., Morse, C. B., Oršulić, S., Rubin, S. C., Gimotty, P. A., & Adams, S. F. (2014) · Gynecologic Oncology · doi:10.1016/j.ygyno.2014.03.565 · Cited by 19
Cited by
High-Grade Serous Ovarian Cancer: Basic Sciences, Clinical and Therapeutic Standpoints
Lisio, M.-A., Fu, L., Goyeneche, A., Gao, Z.-H., & Telleria, C. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20040952 · Cited by 680
Developing Organoids from Ovarian Cancer as Experimental and Preclinical Models
Maenhoudt, N., Defraye, C., Boretto, M., Jan, Z., Heremans, R., Boeckx, B., Hermans, F., Arijs, I., Cox, B., Van Nieuwenhuysen, E., et al. (2020) · Stem Cell Reports · doi:10.1016/j.stemcr.2020.03.004 · Cited by 186
PARP Inhibitors in Ovarian Cancer
Mittica, G., Ghisoni, E., Giannone, G., Genta, S., Aglietta, M., Sapino, A., & Valabrega, G. (2018) · Recent Patents on Anti-Cancer Drug Discovery · doi:10.2174/1574892813666180305165256 · Cited by 158
Moore, K. N., O'Malley, D. M., Vergote, I., Martin, L. P., Gonzalez-Martin, A., Malek, K., & Birrer, M. J. (2018) · Gynecologic Oncology · doi:10.1016/j.ygyno.2018.07.017 · Cited by 82
Metadata
- Authors
- Pignata, S., C Cecere, S., Du Bois, A., Harter, P., & Heitz, F.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2017-11
- Volume
- 28
- Issue
- suppl_8
- Pages
- viii51-viii56
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2772815803
- Cited by
- 338
- References
- 34
- FWCI
- 17.30
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.